Hereditary Hemorrhagic Telangiectasia (HHT) Center
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Hereditary Hemorrhagic Telangiectasia (HHT) Center Program aims to reduce the morbidity and mortality associated with HHT by collaborating with clinical centers to improve access to and coordination of care for patients. It focuses on developing innovative approaches to assist healthcare providers in identifying and diagnosing HHT cases more effectively. A significant component of the program is the establishment of a de-identified, aggregated patient data registry designed to enhance understanding of this rare disorder and improve treatment outcomes. Managed by the Health Resources and Services Administration under the Department of Health and Human Services, this initiative encourages partnerships that foster better clinical management and research. The program is presented as a forecast opportunity, with contact available through Nordia Williams for further information. Although specific geographic or organizational details are not provided, the program underscores a national effort to address the complexities of HHT through data-driven strategies and enhanced clinical collaboration.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
